Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650285 | 0.83 | KMT2A (0.43) | KMT2AMEN1PRMT5WDR77BLM | |
| SCHEMBL4650499 | 0.78 | KMT2A (0.51) | KMT2AMEN1POLBPRMT5WDR77 | |
| SCHEMBL4650250 | 0.77 | CFTR (0.43) | POLBOPRM1OPRD1OPRK1 | |
| SCHEMBL6240572 | 0.77 | KMT2A (0.70) | KMT2AMEN1POLBPRMT5WDR77 | |
| SCHEMBL4649495 | 0.77 | PRMT5 (0.46) | KMT2AMEN1POLBPRMT5WDR77 | |
| SCHEMBL1014404 | 0.77 | S1PR5 (0.50) | KMT2A | |
| SCHEMBL4924735 | 0.77 | TSHR (0.48) | OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL4786521 | 0.76 | KMT2A (0.73) | KMT2AMEN1POLBPRMT5WDR77 | |
| SCHEMBL13073431 | 0.76 | KMT2A (0.85) | KMT2AMEN1POLBPRMT5WDR77 | |
| SCHEMBL19972744 | 0.76 | KMT2A (0.85) | KMT2AMEN1POLBPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255188-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-16 | — | — | US | claimed |
| US-20080255188-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255188-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | KMT2A 3036/4885MEN1 1581/4885POLB 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.